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Progression of HCV infection in patients with chronic
kidney disease: Reply
To the Editor:
We thank Dr. Cholongitas and colleagues for their
comments on our recent review in this Journal on
HCV in patients with chronic kidney disease (CKD)
and for highlighting ﬁndings from other groups who
have performed liver biopsies in these patients. As they
note we had suggested in a paper several years ago that
hemodialysis or perhaps uremia may provide some pro-
tective eﬀect against ﬁbrosis development in patients
with HCV infection [1]. As cited in our paper, an inter-
national group of hepatologists and nephrologists has
developed guidelines, under the auspices of the National
Kidney Foundation, to guide the management of pa-
tients with CKD and HCV infection [2]. Prospective
studies with serial liver biopsies are clearly required in
this patient population to further deﬁne the natural his-
tory of HCV infection at various stages of CKD includ-
ing post renal transplantation particularly as treatment
options for HCV expand.
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Hepatitis E virus as an emerging cause of chronic liver disease
in organ transplant recipients
To the Editor:
We read with great interest the very complete and up-
to-date review by R.H. Purcell and S.U. Emerson on
hepatitis E virus (HEV) [1]. It highlights that this virus
is the leading or the second leading cause of acute hep-
atitis in adults in many parts of the developing world,
and that an increasing number of sporadic autochtho-
nous acute hepatitis E cases have been recently reported
in industrialized countries [1]. Unexpectedly, a new clin-
ical feature has just been described in association with
autochthonous hepatitis E virus (HEV) infections in
developed countries [2–4]. Indeed, since February
2008, cases of HEV-related chronic hepatitis have been
reported in organ transplant recipients by three diﬀerent
teams, including ours. This ﬁnding still adds signiﬁcant
interest to hepatitis E, and questions the extent and
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